Genotypes of Common Polymorphisms in the PON1 Gene Associated with Paraoxonase Activity as Cardiovascular Risk Factor

Prenatal Exposure to Per- and Polyfluoroalkyl Substances, Umbilical Cord Blood DNA Methylation, and Cardio-Metabolic Indicators in Newborns: The Healthy Start Study

“…Genes associated with the significant DMRs were involved in lipid metabolism, growth, and cardiovascular disease risk, as well as functions of the immune and nervous systems. Notably, PFOA, PFNA, and PFDA had DMRs annotated to the PON1 gene, previously linked to lipid oxidation (Luo et al 2018), HDL functionality (Mahrooz et al 2019) and cardiovascular disease (Moreno-Godínez et al 2018), and the related PON3 gene, previously linked with atherosclerotic disease (Rull et al 2012). DMRs associated with PFOA were also annotated to NR1H2, involved in lipid homeostasis and inflammation; and RPTOR, part of the mTOR complex that regulates cell growth in response to nutrient availability.…”

Associação do Genótipo e Fenótipo da Paraoxonase-1 com Angiografia Positiva para Doença Arterial Coronariana

“…Em uma metanálise de associados com atividade enzimática diminuída foram AT/ TT de rs850560 e AA de rs662. 22 Esses resultados foram compatíveis com nossos achados, embora tenha sido uma metanálise nacional conduzida na população do México e, portanto, a etnia era diferente.…”

Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population

“…42 Numerous studies have shown that altered levels of PON1 lead to atherosclerosis and cardiac events, highlighting the positive association between the PON1 Q192R variant and both CAD susceptibility and 10-year survival. [8][9][10][11][12][13][14][15][16][17][18][19]33 To determine this relationship in a Latin-American population, we genotyped PON1 p.Q192R in a cohort of patients with CAD. Our results illustrate a positive association between this variant and susceptibility to CAD in the Colombian population, finding that the 192R allele confers a lower risk of developing CAD under a dominant genetic model (OR, 0.58; 95% CI, 0.42-0.8; P < 0.01).…”

“…10 The PON1 p. Q192R missense variant (c.575A>G, rs662) is the most extensively characterized PON1 SNP and has been associated with CAD susceptibility in numerous studies. [11][12][13][14][15][16][17][18][19] Intriguingly, other studies could not replicate this association, whereby the role of PON1 Q192R in CAD remains controversial. [20][21][22] PON1 is considered a key factor for the bioactivation and clinical activity of clopidogrel, an ADP P2Y12 receptor antagonist recommended as a first-line treatment for ACS.…”

“…Allelic and genotypic frequencies were obtained from numerous studies for comparisons. [11][12][13][14][15][16][17][18][19][20][21][22][33][34][35][36][37][38][39][40][41] The P value for significance was set at < 0.05. Analyses were conducted using R v4.0.3 (R Core Team, 2014) or SPSS v26 208 software (IBM Analytics).…”